Replies to post #32404 on RespireRx Pharmaceuticals Inc (fka RSPI)

[zebra4o1]

Do we really have proof of efficacy in RD? I certainly feel that we do, but is that how a prospective partner would interpret the data? Just cannot understand why nobody seems to want the RD indication.

[atheroprevent]

Enemem, making the best out of Cor doing "nothing"

Selling Cor 2009 offset some cap gains 2009.

Despite low vol, 2010 Cor purchase, 30+ days later, is looking good, at least on paper this year with 50%+ return.

Despite all this, ampakines have not provided or preserved analgesia from Cor investment................so far?

[neuroinv]

Ordinarily, I'd be tempted to agree. But this presumes some sort of 'everything else being the same' context. And nothing has been stable in pharma over the past seventeen months: The economy, the M&A, the layoffs--everything has been in flux. And continues to be.

NeuroInvestment